Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study-Reference-Cited by-同舟云学术

Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study

Published:2014-05-24 Issue:7 Volume:37 Page:521-528
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Chou Hsin-Chun,Chen Wen-Wen,Hsiao Fei-Yuan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/content/pdf/10.1007/s40264-014-0171-x.pdf

Reference31 articles.

1. Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf. 2013;12:545–57.

2. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. 2010;64:984–90.

3. Cohen D. Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. BMJ. 2013;346:f2607.

4. Sue M, Yoshihara A, Kuboki K, Hiroi N, Yoshino G. A case of severe acute necrotizing pancreatitis after administration of sitagliptin. Clin Med Insights Case Rep. 2013;6:23–7.

5. Garg R, Hussey C, Ibrahim S. Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report. Diabet Med. 2010;27:485–6.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study;Frontiers in Pharmacology;2024-07-04

2. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials;Expert Opinion on Drug Safety;2021-11-10

3. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors;Current Drug Safety;2021-06-08

4. Using real‐world evidence for pharmacovigilance and drug safety‐related decision making by a resource‐limited health authority: 10 years of experience in Taiwan;Pharmacoepidemiology and Drug Safety;2020-09-07

5. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes;Metabolism;2020-08